| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Topline Data Readout example | Phase 3 | — | Subscribe to access the data. | Biologics | Nervous System | ||
Topline Data Readout example | Phase 3 | — | Subscribe to access the data. | Biologics | Nervous System | ||
Topline Data Readout example | Phase 3 | — | Subscribe to access the data. | Biologics | Nervous System |
Recent Updates
Recently added Catalysts
Immunovant, Inc.$39.71
-1.48 (-3.61%)
C 40Pipeline Score Richly Valued Biotech · Clinical
Market Cap
7.01 B
EPS
-2.77
P/E Ratio
-
Value Trade
58.35 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
142.29 M
Operating CF
-101.83 M
Total Assets
957.01 M
Total Liabilities
104.42 M
Equity
852.59 M
D/E Ratio
12,345
19.45 %
Week
19.61 %
1 Month
30.49 %
3 Month
53.83 %
6 Month
120.32 %
5 Year
243.22 %
All Time
Cash Data
Cash Position
902.11 M
Monthly Burn
33.94 M
Runway
25.1 mo
Burn Trend
StableSEC Filing
May 20, 2026
Overview
Volume
1.10 M
52 Week Range
13.79 - 36.29
% held by Insiders
60.37 %
% held by Institutions
51.79 %
Enterprise Value
6.11 B
Total Shares
203.32 M
Short %
23.77 %
Float Shares
79.09 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Immunovant, Inc.
236Total events
3Upcoming
58Tier-1 (high impact)
2019 – 2027Coverage
Upcoming catalysts 3
Event history 233
Q3 2026
◆Topline ReadoutIMVT-1402Clinical Data
Further updates on D2T RA program expected in 2H 2026
difficult-to-treat rheumatoid arthritissource ↗
May 20, 2026
◆Quarterly UpdateCorporate
Report financial results for Q4 and fiscal year ended March 31, 2026, and provide business update
May 20, 2026
▲Full ResultsIMVT-1402Clinical Data
Preliminary Week 16 results from IMVT-1402 trial in D2T RA: ACR20 72.7%, ACR50 54.5%, ACR70 35.8%
difficult-to-treat rheumatoid arthritissource ↗
May 20, 2026
▲Enrollment CompleteIMVT-1402Trial
Proof-of-concept trial in CLE fully enrolled
cutaneous lupus erythematosussource ↗
Apr 2, 2026
▼Topline ReadoutBatoclimabClinical Data
Phase 3 topline results for batoclimab in TED
thyroid eye diseasesource ↗
Apr 2, 2026
▼Primary Endpoint MissedBatoclimabClinical Data
Phase 3 studies missed primary endpoint
thyroid eye diseasesource ↗
Apr 2026
▼Topline ReadoutBatoclimabClinical Data
Topline results from two Phase 3 studies of batoclimab in TED: neither met primary endpoint
thyroid eye diseasesource ↗
Apr 2026
▼Program DiscontinuationBatoclimabCorporate
Discontinued further development of batoclimab across all indications
Mar 31, 2026
◆Trial InitiationIMVT-1402Trial
Anticipates initiating clinical trials in ten indications by March 31, 2026
Mar 31, 2026
◆Timing GuidanceIMVT-1402Presentation
Anticipates initiating clinical trials in 10 indications by March 31, 2026
Feb 6, 2026
◆Quarterly UpdateCorporate
Immunovant to report Q3 FY2025 financial results and provide business update
Drug Pipeline Intelligence
C40
Pipeline Score $604M
Pipeline ValueRichly Valued
Valuation Signal6
Drugs Scored0.1x
rNPV / MCap Top 57%
Small Cap (rank 393 of 911)
Percentile RankImmunovant, Inc. carries a moderate pipeline score (40/100), with $929M risk-adjusted pipeline value, led by IMVT-1402 in Subacute Cutaneous Lupus Erythematosus (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IMVT-1402 Small molecule | Generalized Myasthenia Gravis | Phase 3 | NCT07039916 | 44% | $480M | RECRUITING | 231 | VERY_FAST | B (67) | Dec 1, 2028 | MODERATE_RISK | LOW Jun 16, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
IMVT-1402 | difficult-to-treat rheumatoid arthritis | — | 2026-05-20 | ACR20: 72.7%; ACR50: 54.5%; ACR70: 35.8% | Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 Read More | |
IMVT-1402 | difficult-to-treat rheumatoid arthritis | — | 2026-05-20 | ACR20: 72.7%; ACR50: 54.5%; ACR70: 35.8% | Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 Read More | |
IMVT-1402 | difficult-to-treat rheumatoid arthritis | — | 2026-05-20 | ACR20: 72.7%; ACR50: 54.5%; ACR70: 35.8% | Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IMVT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IMVT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
IMVT▲ +35.3%on this news
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026
Immunovant, Inc. reported positive clinical results for IMVT-1402, showing significant response rates in a trial for difficult-to-treat rheumatoid arthritis. The company is on track for further updates in 2026, including topline data from a cutaneous lupus erythematosus trial. Despite a substantial net loss, Immunovant's cash reserves support ongoing development efforts.
Read more →IMVTImmunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
Immunovant (Nasdaq: IMVT) has announced that it will report its financial results for the fourth quarter and fiscal year ending March 31, 2026, on May 20, 2026. The company will also provide a business update during a conference call scheduled for 8:00 a.m. ET. This event underscores Immunovant's commitment to transparency and engagement with stakeholders.
Read more →IMVTImmunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
Immunovant announced that its Phase 3 studies of batoclimab for thyroid eye disease did not meet their primary endpoint. Despite this, patients showed improvement in proptosis after high-dose treatment. The company plans to review the development of batoclimab with its partner HanAll Biopharma and continue advancing its other candidate, IMVT-1402.
Read more →IMVT▲ +12.4%on this news
Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025
Immunovant reported its financial results for Q3 2025, highlighting a fully enrolled trial for IMVT-1402 with topline data expected in 2026. The company raised $550 million in financing, extending its cash runway. Upcoming data for batoclimab in thyroid eye disease is also anticipated in early 2026. However, the company recorded a slight increase in net loss compared to the previous year.
Read more →IMVTImmunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
Immunovant has announced it will report its financial results for Q3 2025 on February 6, 2026. The company will also provide a business update during the conference call. Investors can access the call via registration, and details will be available on the Immunovant website. The company focuses on developing therapies for autoimmune diseases.
Read more →IMVT▲ +5.3%on this news
Immunovant Announces Pricing of $550 Million Common Stock Financing
Immunovant, Inc. has announced the pricing of an underwritten offering of common stock, aiming to raise approximately $550 million. The funds will support the company's operations and capital expenditures, particularly for the anticipated launch of IMVT-1402 for Graves' Disease. The offering is expected to close on December 12, 2025, pending customary conditions.
Read more →IMVTImmunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025
Immunovant reported its financial results for the second quarter ended September 30, 2025, highlighting a strong cash position and promising clinical trial results for its drug IMVT-1402. The company anticipates topline results from several trials in 2026 and 2027. However, it also noted an increase in net loss and R&D expenses compared to the previous year.
Read more →IMVT▲ +13.1%on this news· ran to +31% by day 3
Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
Immunovant (Nasdaq: IMVT) announced it will report its financial results for the second quarter ended September 30, 2025, on November 10, 2025, at 8:00 a.m. ET. The company will also provide a business update during this call. Information regarding the conference call can be found on Immunovant’s investor website, where the archived webcast will be accessible post-call. Immunovant focuses on targeted therapies for individuals with autoimmune diseases.
Read more →IMVTIMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT
The law firm Kahn Swick & Foti, LLC has begun an investigation into Immunovant, Inc. regarding its officers and directors. The inquiry focuses on potential breaches of fiduciary duties and possible violations of state or federal laws. Shareholders of Immunovant are urged to contact the firm to discuss their legal rights. This development may pose risks to the company's leadership and shareholder interests.
Read more →IMVT▲ +9.3%on this news
Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
Immunovant, Inc. has announced promising six-month off-treatment data for batoclimab in uncontrolled Graves' disease patients. The results, to be presented at the 2025 ATA Annual Meeting, suggest the potential for disease modification and strong treatment durability. The company believes these findings could significantly change treatment approaches for Graves' disease if approved by the FDA.
Read more →IMVTImmunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended
Immunovant, Inc. reported corporate updates and financial results for the quarter ended June 30, 2025, highlighting the initiation of two potentially registrational trials for its therapy IMVT-1402 in Graves' disease and Sjögren's disease. The company maintains a strong cash position of approximately $598.9 million, enabling ongoing clinical trials across multiple indications, with key results expected by 2027. However, Immunovant also reported a net loss of $120.6 million for the quarter, an increase from the previous year, attributed to higher R&D expenses.
Read more →IMVT▲ +5.6%on this news
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended
Immunovant, Inc. has made significant strides with its lead candidate IMVT-1402, focusing on rapid clinical execution for six announced indications. The company plans to initiate multiple potentially registrational studies in diseases such as Graves’ disease and Sjögren's disease by summer 2025. Financial results reveal an increased net loss compared to the previous year, primarily driven by higher R&D expenses, despite a strong cash position of $714 million for ongoing operations. Positive data from prior trials reinforces the potential of IMVT-1402 as a leading treatment in autoimmune diseases.
Read more →IMVTImmunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
Immunovant, Inc. has announced a strategic transition with Eric Venker appointed as CEO, succeeding Pete Salzmann. The company is expanding its IMVT-1402 program to include Sjögren's Disease and Cutaneous Lupus Erythematosus, aiming for best-in-class treatment options. This leadership change comes as development activities for previous treatments conclude.
Read more →IMVTImmunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
Immunovant announced positive topline results from its Phase 3 study of batoclimab in Myasthenia Gravis (MG) and initial results from a Phase 2b study in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The studies demonstrated significant improvements in clinical outcomes, with batoclimab achieving its primary endpoint in MG. The company plans to leverage these results to advance its lead asset, IMVT-1402.
Read more →IMVTImmunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
Immunovant, Inc. will host an investor webcast on March 19 at 8:00 AM ET to discuss results from its Phase 3 study of batoclimab in myasthenia gravis and initial findings from its Phase 2b study in chronic inflammatory demyelinating polyneuropathy. The event will feature CEO Pete Salzmann and Roivant's CEO Matt Gline. A replay will be available after the event.
Read more →IMVT▼ -9.6%on this news
Immunovant Reports Financial Results for the Quarter Ended December 31, 2024
Immunovant reported its financial results for Q3 2024, highlighting progress in the development of its lead asset, IMVT-1402. The company has cleared six INDs and plans to initiate clinical trials for ten indications by March 2026. Despite a significant net loss of $111.1 million, Immunovant remains optimistic about upcoming data readouts and the potential of IMVT-1402 in treating autoimmune diseases.
Read more →IMVTForward-looking statements 2 This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities la
Immunovant presented forward-looking statements revealing its plans for the development of IMVT-1402 and batoclimab for autoimmune diseases at the J.P. Morgan Healthcare Conference. The company's focus includes initiating pivotal trials, expanding patient indications, and enhancing financial viability through a healthy cash position. However, the company cautioned about inherent risks and uncertainties affecting trial outcomes and regulatory processes. The lead asset IMVT-1402 is positioned to potentially address several autoimmune indications with anticipated milestones next year.
Read more →IMVTImmunovant Announces $450 Million Private Placement
Immunovant, Inc. has announced a private placement of 22.5 million shares at $20 each, raising approximately $450 million. The funds will be used to advance its development pipeline, particularly for its lead asset IMVT-1402. The transaction is expected to close around January 15, 2025, pending customary conditions.
Read more →IMVTImmunovant Provides Development Updates and Reports Financial Results for the Quarter Ended
Immunovant reported positive developments regarding its lead asset, IMVT-1402, announcing five cleared IND applications across several therapeutic areas. Notable advancements include proof-of-concept data for IMVT-1402 in Graves' disease, suggesting the potential for transformative treatment in patients inadequately controlled on existing therapies. The company plans to initiate multiple registrational trials by March 2025, while also facing challenges from increased competition in thyroid eye disease trials. Financial challenges were highlighted, with a significant rise in R&D expenses as the company scales its clinical endeavors.
Read more →IMVTImmunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting
Immunovant, Inc. announced that their Phase 2a trial data for batoclimab in Graves' disease will be presented at the upcoming American Thyroid Association Annual Meeting. The oral presentation will cover the efficacy and safety of the FcRn inhibitor, highlighting both thyroid-specific and extrathyroidal manifestations of the disease. The meeting will take place from October 30 to November 3, 2024, in Chicago, Illinois.
Read more →IMVT▼ -7.6%on this news
Immunovant Provides Update on Graves' Disease Development Program High dose batoclimab achieved 76% response rate in patients uncontrolled on antithyroid drugs (ATDs) at week 12 High dose batoclimab achieved 56% ATD-free
Immunovant, Inc. (Nasdaq: IMVT) announced positive results from a Phase 2a trial of batoclimab for Graves' Disease, showing a 76% response rate and a 56% ATD-free response rate at week 12 in patients previously uncontrolled on antithyroid drugs. The data revealed a significant correlation between IgG reduction and clinical outcomes, suggesting potential for IMVT-1402 as a first-in-class treatment. The company expects to initiate a pivotal trial by the end of 2024, following FDA clearance. This reflects a growing unmet medical need within this patient population.
Read more →IMVT▲ +9.5%on this newsshared move
Immunovant to Host Graves’ Disease Program Update on September 9, 2024
Immunovant, Inc. will host an investor webcast on September 9, 2024, to provide updates on its Graves' Disease program. The webcast will present new epidemiologic data, results from the Phase 2 study of batoclimab, and an overview of the IMVT-1402 development program. This event signifies the company's ongoing commitment to development in autoimmune diseases and its innovative approach in the field.
Read more →IMVTImmunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended
Immunovant, Inc. reported financial results for the fiscal first quarter ended June 30, 2024, highlighting significant progress in its clinical development programs. The company completed enrollment in the pivotal trial for batoclimab in Myasthenia Gravis and is on track to initiate a registrational program for IMVT-1402 by the fiscal year end. Immunovant also reported a solid cash position of approximately $560 million but faced net losses and increased expenses related to ongoing development efforts. The company continues to focus on expanding its innovative therapies for autoimmune diseases.
Read more →IMVTImmunovant Awarded U.S. Patent for IMVT-1402
Immunovant, Inc. has received a U.S. patent for its antibody IMVT-1402, designed to target FcRn, with the patent covering its composition and manufacturing methods until June 2043. Preliminary clinical trial results suggest that IMVT-1402 may be best-in-class, demonstrating a significant reduction in IgG levels without adverse changes in serum albumin and cholesterol. However, the company acknowledges various risks related to the predictive nature of early trial results and challenges in securing regulatory approvals for its therapies.
Read more →IMVT▼ -6.3%on this news
Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Immunovant, Inc. announced that its CEO, Pete Salzmann, will present a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. The presentation aims to outline the company's initiatives and developments in targeting autoimmune diseases through anti-FcRn technology. Stakeholders can access the live webcast and an archived version on Immunovant's website post-presentation. This showcases the company's ongoing commitment to innovation in immunology.
Read more →IMVT▼ -12.8%on this news
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease
Immunovant, Inc. announced positive initial results from a Phase 2 clinical trial of batoclimab for Graves' disease, showing over 50% response rates. The trial, which involves patients who are still hyperthyroid despite treatment, demonstrated significant IgG reduction, particularly with the higher dose of 680 mg batoclimab. The company views this as a promising treatment option in a field with high unmet medical needs. Future development plans for batoclimab and its other product IMVT-1402 will be clarified in 2024.
Read more →IMVT▲ +7.4%on this news· ran to +21% by day 3
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential Results from the 600 mg MAD cohort for IMVT-1402 similar to previously disclosed results from the 300 mg MAD cohort
Immunovant, Inc. announced positive initial results from the 600 mg multiple-ascending dose (MAD) cohort of its Phase 1 clinical trial for IMVT-1402 in healthy adults. The data indicates a significant mean IgG reduction akin to high-dose batoclimab, with minimal impacts on albumin and LDL-C levels. This suggests IMVT-1402's potential as a best-in-class anti-FcRn antibody for treating IgG-mediated autoimmune diseases. The promising profile and pharmacodynamic outcomes may allow Immunovant to explore a diverse portfolio of indications.
Read more →IMVTImmunovant to Present at Upcoming Investor Conferences
Immunovant, Inc. announced that its CEO, Pete Salzmann, will take part in several upcoming investor conferences, including the Stifel 2023 Healthcare Conference and Evercore ISI 6th Annual HealthCONx Conference. These events are scheduled for mid to late November 2023, providing opportunities for insights into the company's efforts in immunology and treatment of autoimmune diseases. The sessions will be accessible via live webcast, emphasizing Immunovant's transparency and engagement with the investment community.
Read more →IMVT▼ -9.8%on this news
Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Immunovant, Inc. has successfully closed its underwritten public offering of 8,475,500 shares at $38.00 each, including additional shares purchased by underwriters. The company also conducted a concurrent private placement of 4,473,684 shares, generating total gross proceeds of around $492.1 million. This offering reinforces Immunovant's financial position as it continues to focus on developing treatments for autoimmune diseases. The offering was facilitated by several prominent bookrunning managers, reflecting significant interest in the company's equity.
Read more →IMVTImmunovant Announces Pricing of $450 Million Common Stock Financing
Immunovant, Inc. is proceeding with a public stock offering priced at $38.00 per share, aiming to raise around $450 million. Concurrently, the company will sell shares to Roivant Sciences in a private placement, also priced at $38.00 per share. This financing is expected to close on October 2, 2023, subject to customary conditions. However, the successful execution of both transactions carries certain uncertainties and risks, particularly related to market conditions and registration requirements.
Read more →IMVT▲ +97%on this newsshared move
Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results IMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously obser
Immunovant, Inc. announced promising initial data from its Phase 1 trial for IMVT-1402, showing significant Immunoglobulin G (IgG) reductions in healthy adults. The drug, delivered via subcutaneous injection, exhibited a similar potency to batoclimab without major adverse effects. The data support IMVT-1402's potential as an effective treatment for IgG-mediated autoimmune diseases. Further multiple-ascending dose results are anticipated in November 2023.
Read more →IMVT▲ +97%on this newsshared move
Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023
Immunovant, Inc. announced it will report initial results from the Phase 1 trial of IMVT-1402 on September 26, 2023. Following the results, a conference call and webcast will be held at 8:00 a.m. ET for discussion. The company is recognized for its commitment to developing targeted therapies for autoimmune diseases, utilizing anti-FcRn technology. This reflects ongoing efforts to address complex healthcare needs in the spectrum of autoimmune disorders.
Read more →IMVT▲ +97%on this newsshared move
Immunovant Announces Proposed Offering of $300 Million of Common Stock
Immunovant, Inc. has announced a proposed offering of $300 million of its common stock, consisting of a $130 million underwritten public offering and a concurrent private placement of $170 million with Roivant Sciences Ltd. The completion of the public offering is subject to market conditions, and there's uncertainty regarding its terms and timing. The offering could enhance Immunovant's financial position but introduces risks due to market dependency.
Read more →IMVTForward-looking Statements 2 This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities la
Immunovant is actively progressing its development of the anti-FcRn products batoclimab and IMVT-1402 across multiple autoimmune disease indications. The company's forward-looking statements outline expectations regarding clinical trials, regulatory discussions, and market potential, although these are subject to various uncertainties. Currently, Immunovant maintains a substantial cash runway to fund operations into the second half of 2025, necessitating continued advancements in its product pipeline. The company also highlights the unique attributes of its product candidates, potentially benefiting patient treatment strategies.
Read more →IMVTImmunovant Reports Financial Results and Recent Business Updates for the Quarter Ended
Immunovant, Inc. reported financial results and updates for its fiscal third quarter ending December 31, 2022. The company plans to initiate a Phase 1 trial of IMVT-1402 in early 2023, with several other trials for its product candidates already underway. Despite a strong cash position of $433 million, the company reported a significant net loss of $63.2 million for the quarter, reflecting increased research and development costs. Leadership remains optimistic about the potential for transformative advancements in autoimmune therapies.
Read more →IMVT▲ +5.1%on this news
Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th
NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., chief executive officer, will participate in a
Read more →IMVT▲ +24%on this news· ran to +42% by day 1
Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock New York
Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock New York, October 4, 2022 (GLOBE NEWSWIRE) Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, tod
Read more →IMVTImmunovant Announces IMVT-1402, a Next Generation Anti-FcRn In animal studies, deep IgG lowering similar to batoclimab with no or minimal impact on albumin and low-density lipoprotein (LDL) was observed. Plan to submit I
Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn In animal studies, deep IgG lowering similar to batoclimab with no or minimal impact on albumin and low-density lipoprotein (LDL) was observed. Plan to submit IND and initiate Phase 1 study in early 2023 with initial d
Read more →IMVTImmunovant to Present at Roivant Investor Day on September 28th
NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will present a corpo
Read more →IMVTImmunovant to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14th
NEW YORK, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in
Read more →IMVTImmunovant Announces Two New Development Programs for Batoclimab
Plan to initiate a Pivotal Phase 2b trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the second half of 20221 with initial results from open-label period 1 expected in the first half of 2024 Plan to initiate a Phase 2 trial in Graves’ Disease in early 2023 wi
Read more →IMVTImmunovant to Host Investor Webcast to Announce Two New Indications for Batoclimab on September 7, 2022
NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, will host a webcast for the investment community to announce two new indications for batoc
Read more →IMVT▼ -8.2%on this news· ran to -20% by day 3
Immunovant Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended
Immunovant Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 Immunovant plans to initiate two placebo-controlled Phase 3 clinical trials
Read more →IMVT▼ -8.6%on this newsshared move
Immunovant to Report Fourth Quarter and Full Year 2022 Financial Results on June 8, 2022
NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that it will report its fourth quarter and full-year 2022 financial result
Read more →IMVTImmunovant to Present at the H.C. Wainwright Global Investment Conference on May 25th
NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fi
Read more →IMVTImmunovant to Present at the UBS Global Healthcare Conference on May 23rd
NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fi
Read more →IMVTImmunovant to Present at LifeSci Partners’ Immunology and Inflammation Symposium on May 10th
NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fi
Read more →IMVTImmunovant to Host Virtual R&D Day on March 30, 2022
NEW YORK, March 28, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that it will host a virtual R&D event on Wednesday, March 30, 2022, from
Read more →IMVTImmunovant to Present at the 11th Annual SVB Leerink Global Healthcare Conference
NEW YORK, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a f
Read more →IMVTImmunovant Reports Financial Results for the Quarter Ended
Immunovant Reports Financial Results for the Quarter Ended December 31, 2021 Company Ended the Quarter With Cash of Approximately $527.0 Million NEW YORK, February 4, 2022 (GLOBE NEWSWIRE) - Immunovant, Inc. (Nasdaq IMVT), a clinical-stage biopharmaceutical company focused on e
Read more →IMVTImmunovant Appoints Mark Levine as Chief Legal Officer
Mr. Levine adds valuable experience to the leadership team as Immunovant accelerates the development of batoclimab with the expected initiation of three pivotal trials in 2022 NEW YORK, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharma
Read more →IMVTImmunovant to Present at the 40th Annual J.P. Morgan Healthcare Conference
Immunovant to Present at the 40th Annual J.P. Morgan Healthcare Conference NEW YORK, Jan. 7, 2022 - Immunovant, Inc. (Nasdaq IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann
Read more →IMVT▲ +7%on this news
Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022
Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022 NEW YORK, December 30, 2021 (GLOBE NEWSWIRE) - Immunovant, Inc. (Nasdaq IMVT), a clinical-stage biopharmaceutical company focused on enabling
Read more →IMVTImmunovant to Present at the Stifel 2021 Virtual Healthcare Conference
Immunovant to Present at the Stifel 2021 Virtual Healthcare Conference NEW YORK, Nov. 12, 2021 - Immunovant, Inc. (Nasdaq IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M
Read more →IMVTImmunovant to Participate in Roivant R D Day 2021
Immunovant to Participate in Roivant R D Day 2021 NEW YORK, Sept. 27, 2021 - Immunovant, Inc. (Nasdaq IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive
Read more →IMVTImmunovant Appoints Renee Barnett as Chief Financial Officer - Ms. Barnett brings a wealth of financial experience to Immunovant - Expands executive leadership team as Immunovant plans to return to the clinic across mult
Immunovant Appoints Renee Barnett as Chief Financial Officer -Ms. Barnett brings a wealth of financial experience to Immunovant -Expands executive leadership team as Immunovant plans to return to the clinic across multiple indications NEW YORK, September 15, 2021 - Immunovant,
Read more →IMVTImmunovant to Report Financial Results for Quarter Ended June 30, 2021
NEW YORK, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that it will host a conference call and audio webcast on Monday, August 9,
Read more →IMVT▼ -26%on this news
Immunovant Receives $200 Million Strategic Investment from Roivant Sciences - Proceeds will fund continued development of IMVT-1401 in multiple indications
Immunovant Receives $200 Million Strategic Investment from Roivant Sciences -Proceeds will fund continued development of IMVT-1401 in multiple indications NEW YORK, August 02, 2021 (GLOBE NEWSWIRE) - Immunovant, Inc. (Nasdaq IMVT), a clinical-stage biopharmaceutical company foc
Read more →IMVTIMMUNOVANT (IMVT) INVESTIGATION ALERT - Andrews & Springer LLC Is Investigating Immunovant, Inc. For Potential Breaches of Fiduciary Duty
WILMINGTON, Del., June 28, 2021 (GLOBE NEWSWIRE) -- Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential securities violations and breach of fiduciary duty claims against Immunovant, Inc. (
Read more →IMVTImmunovant Provides Corporate Updates and Reports Financial Results for the Quarter and Fiscal Year Ended March 31, 2021
Immunovant plans to resume clinical development of IMVT-1401 in Myasthenia Gravis (MG) and Warm Autoimmune Hemolytic Anemia (WAIHA) as well as initiate two additional mid-to-late stage studies in the next year Program-wide data review suggests that IMVT-1401 has a broader therap
Read more →IMVTImmunovant, Inc. Technology Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
Investors with losses are encouraged to contact the firm before April 20, 2021; click here to submit trade information LOS ANGELES, April 14, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Immunovant, Inc.
Read more →IMVTImmunovant Reports Financial Results for the Quarter and Nine Months Ended
Immunovant Reports Financial Results for the Quarter and Nine Months Ended December 31, 2020 Company Ended the Quarter With Cash of Approximately $422 Million NEW YORK, Feb. 16, 2021 - Immunovant, Inc. (Nasdaq IMVT), a clinical-stage biopharmaceutical company focused on enablin
Read more →IMVTImmunovant, Inc. Investors: Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Feb. 10, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Immunovant, Inc. ("Immunovant" or the "Company") (NASDAQ: IMVT) investors that the firm has initiated an investig
Read more →IMVTImmunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401
Immunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401 NEW YORK, Feb. 2, 2021 - Immunovant (Nasdaq IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today announced a voluntary pause of dosing
Read more →IMVTImmunovant Appoints Rita Jain Chief Medical Officer And Provides Corporate Update
Dr. Jain brings deep expertise in the design and execution of complex clinical trials, having overseen the development of more than 15 new chemical entities and marketed products Dr. Jain’s broad and diverse clinical experience makes her uniquely well-suited to lead the initiati
Read more →IMVTImmunovant Reports Financial Results for the Quarter and Six Months Ended
Immunovant Reports Financial Results for the Quarter and Six Months Ended September 30, 2020 Company Ended the Quarter With Cash of Approximately $444 Million NEW YORK, November 12, 2020 - Immunovant, Inc. (Nasdaq IMVT), a clinical-stage biopharmaceutical company focused on ena
Read more →IMVTImmunovant Announces Closing of $200.0 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
NEW YORK, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today announced the closing of its previously announced underwritten public offering of
Read more →IMVTImmunovant Announces Pricing of Public Offering
NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced the pricing of its underwritten public offering of 5,270,093 shares of its common stock at a price to the public of $33.00 per share. The aggregate gross proceeds to Immunovant from the o
Read more →IMVTImmunovant Announces Positive Topline Results from Multi-Center, Placebo-Controlled Phase 2a Trial of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Myasthenia Gravis Compan
Immunovant Announces Positive Topline Results from Multi-Center, Placebo-Controlled Phase 2a Trial of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Myasthenia Gravis Company to Host Conference Call on August 25, NEW YORK, August
Read more →IMVTImmunovant Appoints Michael Elliott Chief Scientific Officer
NEW YORK, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today announced the appointment of Michael Elliott, MBBS, PhD as Chief Scientific Office
Read more →IMVTImmunovant Reports Financial Results for the Quarter and Fiscal Year Ended
Immunovant Reports Financial Results for the Quarter and Fiscal Year Ended March 31, 2020 and Announces Plans for Phase 3 Registrational Trial of IMVT-1401 in Myasthenia Gravis NEW YORK, June 29, 2020 (GLOBE NEWSWIRE) Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmac
Read more →IMVTImmunovant Announces Redemption of Warrants and Achievement of First Earnout Milestone under Share Exchange Agreement
Immunovant Announces Redemption of Warrants and Achievement of First Earnout Milestone under Share Exchange Agreement May 14, 2020 (GLOBE NEWSWIRE) Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with aut
Read more →IMVTImmunovant Announces Closing of $139.4 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
NEW YORK, April 16, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today announced the closing of its previously announced underwritten public offering of
Read more →IMVTImmunovant Announces Pricing of $121.2 Million Public Offering
NEW YORK, April 14, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today announced the pricing of its underwritten public offering of 8,359,448 shares of
Read more →IMVTImmunovant Announces Positive Clinical Results from Ongoing Phase 2a Proof-of-Concept Study of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Thyroid Eye Disease Company to
Immunovant Announces Positive Clinical Results from Ongoing Phase 2a Proof-of-Concept Study of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Thyroid Eye Disease Company to Host Conference Call on March 30, 2020 at 8:30am EDT NEW Y
Read more →IMVTImmunovant Reports Financial Results for the Quarter and Nine Months Ending
Immunovant Reports Financial Results for the Quarter and Nine Months Ending December 31, 2019 NEW YORK, February 14, 2020 / PRNewswire / Immunovant, Inc. (NASDAQ: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune dis
Read more →IMVTImmunovant to Present at the 9th Annual SVB Leerink Global Healthcare Conference
NEW YORK, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, announced today that Pete Salzmann, Chief Executive Officer, will provide a corporate ov
Read more →IMVTImmunovant Sciences Ltd. Closes Transaction with Health Sciences Acquisitions Corporation Combined company, to be named Immunovant, Inc., will begin trading on Nasdaq under ticker symbol IMVT on
Immunovant Sciences Ltd. Closes Transaction with Health Sciences Acquisitions Corporation company, to be named Immunovant, Inc., will begin trading on Nasdaq under ticker symbol IMVT on December 19, 2019 Immunovant, Inc., formerly known as Health Sciences Acquisitions Corporat
Read more →IMVTHealth Sciences Acquisitions Corporation Sets Date for Special Meeting of Stockholders to Vote on Transaction with Immunovant Sciences Ltd. NEW YORK - Health Sciences Acquisitions Corporation ( HSAC, NASDAQ: HSAC), a spe
Acquisitions Corporation Sets Date for Special Meeting of Stockholders to Vote on Transaction with Immunovant Sciences Ltd. - Health Sciences Acquisitions Corporation ("HSAC," NASDAQ: HSAC), a special purpose acquisition company sponsored by RTW Investments, LP, announced today
Read more →IMVTImmunovant Initiates Dosing in ASCEND-GO 2, a Phase 2b Trial of IMVT-1401 in Patients with Graves' Ophthalmopathy (GO) IMVT-1401, a fully human anti-FcRn antibody designed to be administered via subcutaneous injection, i
Immunovant Initiates Dosing in ASCEND-GO 2, a Phase 2b Trial of IMVT-1401 in Patients with Graves' Ophthalmopathy (GO) YORK and BASEL, Switzerland, November 25, 2019 /PRNewswire/ - Immunovant, a clinical-stage biopharmaceutical company focused on enabling normal lives for pati
Read more →IMVTCorporate Overview November 2019
Corporate Overview November 2019 This presentation has been prepared by Immunovant Sciences Ltd. ("we," "us," "our," "Immunovant" or the "Company") and contai ns forward - looking statements. In some cases, you can identify forward - looking statements by the words "anticipate,"
Read more →IMVTGraves' Ophthalmopathy (GO), or thyroid eye disease, is an autoimmune disease mediated by pathogenic IgG ( pIgG ) that targets the thyroid - stimulating hormone receptor (TSHR) and
Graves' Ophthalmopathy (GO), or thyroid eye disease, is an autoimmune disease mediated by pathogenic IgG ( pIgG ) that targets the thyroid - stimulating hormone receptor (TSHR) and triggers adipogenesis and hyaluronic acid production in orbital fibroblasts resulting in tissue exp
Read more →IMVTThis report is prepared solely
This report is prepared solely for the use of John Strumbos 212-497-0856/310-473-2942 josh.schimmer@evercoreisi.com Ravi.Mehrotra@EvercoreISI.com maneka.mirchandaney@evercoreisi.com Neeraj.Koduri@evercoreISI.com Angela.Ni@evercoreISI.com PM Corner: A Conversation With RTW
Read more →IMVTO R P O R A T E P A R T I C I P A N T S
O R P O R A T E P A R T I C I P A N T S Roderick Wong, Chief Executive Officer, Health Sciences Acquisitions Corporation Pete Salzmann, Chief Executive Officer, Immunovant Naveen Yalamanchi, Chief Financial Officer, Executive Vice President, Health Sciences Acquisitions Corpor
Read more →IMVTHealth Sciences Acquisitions Corporation and Immunovant to Host Joint Conference Call for the Investment Community on Friday, October 11, at 8:30am EDT NEW YORK and LONDON
Health Sciences Acquisitions Corporation and Immunovant to Host Joint Conference Call for the Investment Community on Friday, October 11, at 8:30am EDT NEW YORK and LONDON, Oct. 8, 2019 /PRNewswire/ -- Health Sciences Acquisitions Corporation ("HSAC,"NASDAQ: HSAC), a special
Read more →IMVTChardan Advises Health Sciences Acquisitions Corporation on Merger with Immunovant
Chardan Advises Health Sciences Acquisitions Corporation on Merger with Immunovant 3, 2019 /PRNewswire/ -- Chardan, a global investment bank, announced today that the firm acted as M&A and Capital Markets Advisor for Health Sciences Acquisitions Corporation's (NASDAQ: HSAC) de
Read more →IMVTImmunovant to Merge with Health Sciences Acquisitions Corporation, Creating New Publicly Listed FcRn-Focused Company - Top shareholders of Immunovant post-closing to include Roivant Sciences and blue-chip biotech investo
to Merge with Health Sciences Acquisitions Corporation, New Publicly Listed FcRn-Focused Company YORK and LONDON, October 2, 2019 /PRNewswire/ - Health Sciences Acquisitions Corporation ("HSAC," NASDAQ: HSAC), a special purpose acquisition company sponsored by RTW Investments,
Read more →IMVTHEALTH SCIENCES ACQUISITIONS CORPORATION INDEX TO FINANCIAL STATEMENT Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of
HEALTH SCIENCES ACQUISITIONS CORPORATION INDEX TO FINANCIAL STATEMENT Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of May 14, 2019 F-3 Notes to the Financial Statement F-4 REPORT OF INDEPENDENT REGISTERED PUBLIC To the Stockholders and the Boar
Read more →Competitive Position
How IMVT ranks across every disease it competes inCompetitive Position is a premium feature
See how IMVT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial